Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback